Lanar D E, Tine J A, de Taisne C, Seguin M C, Cox W I, Winslow J P, Ware L A, Kauffman E B, Gordon D, Ballou W R, Paoletti E, Sadoff J C
Department of Immunology, Walter Reed Army Institute of Research, Washington, DC 20307, USA.
Infect Immun. 1996 May;64(5):1666-71. doi: 10.1128/iai.64.5.1666-1671.1996.
NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) were evaluated in the Plasmodium berghei rodent malaria model system. Immunization of mice with a NYVAC-based CSP recombinant elicited a high level of protection (60 to 100%). Protection did not correlate with CS repeat-specific antibody responses and was abrogated by in vivo CD8+ T-cell depletion. Protection was not enhanced by modification of the subcellular localization of CSP. These results suggest the potential of poxvirus-based vectors for the development of vaccine candidates for human malaria.
在伯氏疟原虫啮齿动物疟疾模型系统中评估了表达环子孢子蛋白（CSP）的基于NYVAC的痘苗病毒重组体。用基于NYVAC的CSP重组体免疫小鼠可引发高水平的保护作用（60%至100%）。保护作用与CS重复序列特异性抗体反应无关，并且在体内CD8 + T细胞耗竭后被消除。CSP亚细胞定位的改变并未增强保护作用。这些结果表明基于痘病毒的载体在开发人类疟疾候选疫苗方面具有潜力。
